Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Joseph D. Khoury, Sarah A. Milgrom, Loretta J. Nastoupil, Elizabeth J. Shpall, Jillian R. Gunther, Sattva S. Neelapu, Sairah Ahmed, Raphael E Steiner, Maria Gule-Monroe, Ranjit Nair, Karine A. Al Feghali, Jason R. Westin, Chelsea C. Pinnix, Chitra Hosing, Nathan Fowler, Tommy Sheu, Penny Fang, Bouthaina S. Dabaja, Christopher R. Flowers, Paolo Strati, Yago Nieto
Publikováno v:
Leukemia & Lymphoma. 62:2400-2407
This study aimed to assess the prognostic value of baseline disease distribution for patients with the secondary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy and radiation (RT). 44 patients with seconda
Autor:
Loretta J. Nastoupil
Publikováno v:
Current Hematologic Malignancy Reports. 16:45-51
Follicular lymphoma is a common indolent non-Hodgkin lymphoma with survival improving in the modern era. Despite favorable responses and improving remission duration, FL remains largely incurable with patterns of relapsing and remitting disease with
Autor:
Ranjit Nair, Mikaela E. Bankston, Ethan B. Ludmir, Swaminathan P. Iyer, Shaoying Li, Jillian R. Gunther, Loretta J. Nastoupil, Sattva S. Neelapu, Sairah Ahmed, Bouthaina S. Dabaja, Vivek Verma, Chi Young Ok, Jason R. Westin, Alma Rodriguez, Penny Fang, Dario Pasalic, L. Jeffrey Medeiros, Paolo Strati, Luis Fayad, Raphael E Steiner, Christopher R. Flowers, Chelsea C. Pinnix, Alexander Augustyn
Publikováno v:
Leukemia & Lymphoma. 62:1361-1369
We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (D...
Autor:
Erin Taylor, Felipe Samaniego, Loretta J. Nastoupil, Lei Feng, Sattva S. Neelapu, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Nathan Fowler, Maria Alma Rodriguez, Michelle A. Fanale
Publikováno v:
Leukemia & Lymphoma. 62:58-67
R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of 90yttrium ibritumomab tiuxetan (90YIT) radioimmunotherapy following first-line induction treatment in patients with
Autor:
Loretta J. Nastoupil, Nada Hamad, John Casey, Chan Yoon Cheah, Andrew Grigg, Collin K. Chin, Peter Wood, Kate Manos, Eliza A Hawkes, Maher K. Gandhi, Katharine L Lewis, Shir Jing Ho, Bryan Do, Julie Crawford, Samar Issa
Publikováno v:
British Journal of Haematology. 192:1049-1053
Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We anal
Autor:
Sattva S. Neelapu, Bouthaina S. Dabaja, Michael W. Morrison, Felipe Samaniego, Linda Chi, Paolo Strati, Raphael E Steiner, Luis Fayad, Chelsea C. Pinnix, Philip A. Thompson, Grace Watson, Rashmi Kanagal-Shamanna, Fateeha Furqan, Loretta J. Nastoupil
Publikováno v:
Leuk Lymphoma
Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin Lymphoma (NHL) that can be further classified into 3 sub-types: nodal, extra-nodal and splenic [1]. MZL rarely involves the central ne...
Autor:
Sattva S. Neelapu, Collin K. Chin, Loretta J. Nastoupil, Mansoor Noorani, Maria Alma Rodriguez, Christopher R. Flowers, Jason R. Westin, Preetesh Jain, Felipe Samaniego, Frederick B. Hagemeister, Nathan Fowler, Yun Qing, Lei Feng, Luis Fayad
Publikováno v:
Leukemia & Lymphoma. 61:2985-2989
Histologic transformation of indolent lymphomas account for 13% of de novo presentations of diffuse large B-cell lymphoma (DLBCL) [1]. Although historically associated with poor outcomes in compari...
Autor:
Ian W. Flinn, M. Lia Palomba, Sattva S. Neelapu, Peter Martin, Jutta K. Neuenburg, Loretta J. Nastoupil, Nathan Fowler, Raul Mena, Ranjana H. Advani, Darrin M. Beaupre, Karl Eckert, Sven de Vos, Mark Knapp, Sumeet Bhatia, Richard E. Davis, Robert T. Chen, Melannie Co, Jerry Ping
Publikováno v:
British Journal of Haematology
Summary This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton’s tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once‐daily ibrutinib 560 mg continuously pl
Autor:
Sattva S. Neelapu, Paolo Strati, Mohamed Amin Ahmed, Hun J. Lee, Michael Wang, Maria Alma Rodriguez, Loretta J. Nastoupil, Fredrick B. Hagemeister, Ranjit Nair, R. Eric Davis, Nathan Fowler, Lei Feng, Simrit Parmar, Raphael E Steiner, Felipe Samaniego, Christopher R. Flowers, Jason R. Westin, Luis Fayad, Mansoor Noorani, Sairah Ahmed, Swaminathan P. Iyer
Publikováno v:
Leukemia & Lymphoma. 61:1380-1387
In 2 randomized phase 3 trials BR resulted in longer progression-free survival (PFS) than frontline R-CHOP in patients with indolent and mantle cell lymphoma. However, in subset analyses of follicu...
Autor:
Mohamed Amin Ahmed, Fredrick B. Hagemeister, Loretta J. Nastoupil, Michael Wang, Sattva S. Neelapu, Chan Cheah, Lei Feng, Jorge E. Romaguera, Nathan Fowler, Alma Rodriguez, Jason R. Westin, Mansoor Noorani, Felipe Samaniego, Luis Fayad, Richard E. Davis, Paolo Strati
Publikováno v:
Haematologica
The impact of pre-treatment maximum standardized uptake value (SUVmax) on the outcome of follicular lymphoma (FL) following specific frontline regimens has not been explored. We performed a retrospective analysis of 346 patients with advanced stage f